Public biotech (Nasdaq: JBIO)
Appears in 1 story
Developing JADE101 for IgA nephropathy, Phase 2 underway
For decades, doctors had no drugs specifically approved for IgA nephropathy, a kidney disease that pushes up to half of patients toward kidney failure within ten years of diagnosis. Since December 2021, the FDA has approved five.
Updated Jun 1
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
